Skip to main content
. Author manuscript; available in PMC: 2016 Nov 9.
Published in final edited form as: Cancer Cell. 2015 Oct 17;28(5):610–622. doi: 10.1016/j.ccell.2015.09.008

Figure 6. Clinical relevance of EphB4 and EpoR expression and ESA treatment in cancer patients.

Figure 6

Representative immunohistochemical-peroxidase staining for (A) EphB4 and (B) EpoR expression in ovarian cancer, and (C) EphB4 and (D) EpoR expression in breast cancer samples. Kaplan-Meier curves of disease-specific mortality for ovarian (E-H) and breast (I-J) cancer patients stratified by tumoral expression of (E) EphB4, (F) EpoR, or (G) both EphB4 and EpoR. (H) Evaluation of disease-specific survival duration of ovarian cancer patients based on ESA-treatment and EphB4 expression; (I) Disease-specific survival analysis of breast cancer patients stratified by ESA treatment; (J) Disease-specific survival of breast cancer patients based on ESA treatment and EphB4 expression. Scale bar represents 50 μm. (See also Figure S6 and Table S3-S7).